Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 17/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26598869 | 1.00 | IRAK4 (0.43) | IRAK4JAK3NUDT1MAP4K1JAK2 | |
| SCHEMBL31436637 | 0.88 | IRAK4 (0.45) | IRAK4 | |
| SCHEMBL26598721 | 0.88 | IRAK4 (0.45) | IRAK4 | |
| SCHEMBL31436589 | 0.88 | IRAK4 (0.45) | IRAK4 | |
| SCHEMBL26598716 | 0.88 | IRAK4 (0.45) | IRAK4 | |
| SCHEMBL31436577 | 0.83 | IRAK4 (0.55) | IRAK4TNF | |
| SCHEMBL26598631 | 0.83 | IRAK4 (0.55) | IRAK4TNF | |
| SCHEMBL31436592 | 0.81 | IRAK4 (0.46) | IRAK4NUDT1TNF | |
| SCHEMBL31678583 | 0.81 | IRAK4 (0.46) | IRAK4NUDT1TNF | |
| SCHEMBL26598816 | 0.81 | IRAK4 (0.46) | IRAK4NUDT1TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270190-A1 | KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-08-28 | — | — | US | disclosed |
| CN-119585250-A | KIT inhibitors | 蓝图药品公司 | 2025-03-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270190-A1 | KIT INHIBITORS | KIT, ABL1, APC | IRAK4 753/4885JAK3 200/4885NUDT1 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.